METASTATIC MALIGNANT SOLID NEOPLASM
Clinical trials for METASTATIC MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new METASTATIC MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for METASTATIC MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo targets Cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs (avelumab and M6620) in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see how well the drugs work together t…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:28 UTC
-
New drug combo aims to stall advanced cancers that failed prior therapy
Disease control OngoingThis phase 2 trial tests whether combining nilotinib (a targeted pill) with paclitaxel (a standard chemo) can shrink or slow advanced solid tumors that have already been treated with taxane chemo and are still growing. About 40 adults with progressive metastatic or refractory sol…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:27 UTC
-
Gene-Tailored drugs aim to shrink brain tumors in new trial
Disease control OngoingThis study tests whether genetic testing can help doctors choose the right drug for people whose cancer has spread to the brain. About 50 adults with solid tumors that have certain gene changes (like NTRK, ROS1, or KRAS) will receive a targeted pill. The goal is to see if these d…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 04:27 UTC
-
Radiation after immunotherapy: a new hope for cancer control?
Disease control OngoingThis study looks at whether giving radiation therapy to cancer patients whose disease has spread or grown after immunotherapy can help control the cancer. About 230 adults with metastatic or blood cancers will receive radiation to see if it stops or shrinks tumors. The goal is to…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
Targeted drug shows promise for Gene-Deficient cancers
Disease control OngoingThis study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack a working SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The main goal is to see if the tumors shrink or stop growing.
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific genetic changes. The goal was to find the best dose and check for side effects, while seeing if the combination could shrink or s…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
Experimental combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tests two oral drugs, ZEN003694 and binimetinib, together in people with advanced solid tumors that have RAS gene changes or triple-negative breast cancer. The goal is to find the safest dose and understand side effects. About 42 adults whose cancer has spr…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of three drugs—copanlisib, nivolumab, and ipilimumab—in people with advanced solid tumors or lymphoma that has not responded to standard treatments. The goal is to find the safest dose and understand side effects. About 64 adults will ta…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
New combo therapy targets tough cancers with gene mutations
Disease control OngoingThis early-phase study tests a drug called neratinib combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have not responded to standard treatments. The tumors must have certain gene changes (EGFR, HER2, HER3, H…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
New drug combo targets hard-to-treat metastatic cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Experimental combo aims to starve and attack tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific mutations in the KRAS or NRAS genes. The goal is to find the safest dose and see if the drugs can shrink tumors or slow their growth. About 96 participa…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New drug cocktail targets Hard-to-Treat cancers with gene mutations
Disease control OngoingThis study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if adding copanlisib to standard immunotherapy works better at controlling tumor growth.…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New combo targets tough cancers: hope for KRAS G12C patients
Disease control OngoingThis study tests whether adding panitumumab to sotorasib works better than sotorasib alone for people with advanced solid tumors that have a specific KRAS G12C mutation. About 105 adults with cancers that have spread will be randomly assigned to one of two groups. The goal is to …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:11 UTC
-
Triple threat against tough cancers: drug combo plus radiation shows promise
Disease control OngoingThis study tests a new combination of two drugs (peposertib and avelumab) plus a special type of radiation for people with advanced solid tumors or bile duct cancers that have spread. The goal is to find the safest dose and see if the treatment can shrink tumors. About 103 adults…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Could a shot of radiation stop bone fractures before they start?
Disease control OngoingThis study tests whether giving radiation therapy to high-risk but painless bone tumors can prevent future fractures, spinal cord pressure, or the need for surgery. About 280 cancer patients with multiple metastases will receive either usual care (like bone-strengthening drugs or…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising combo targets Hard-to-Treat HER2 cancers
Disease control TerminatedThis early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together for people with advanced solid tumors that have HER2 gene changes. The study includes up to 33 adults whose cancer has spread or cannot be removed by surgery. Th…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests the safety of adding the drug atezolizumab after a patient's own immune cells have been collected, multiplied, and infused back to fight cancer. It includes 40 adults with advanced blood or solid tumors that no longer respond to standard treatments. T…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Drug duo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs—pembrolizumab and interleukin-12—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose, and to see if the combo can help the immune s…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for cancer patients with organ failure: early trial combines targeted drug with chemo
Disease control OngoingThis early-phase study tests a drug called veliparib combined with two standard chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors who also have liver or kidney dysfunction. The main goals are to find the safest dose and understand how the body p…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug targets Cancer's fuel source in Gene-Mutated tumors
Disease control OngoingThis study tests a drug called telaglenastat (CB-839) that blocks an enzyme tumors need to grow. It is for people with advanced solid tumors or malignant peripheral nerve sheath tumors that have certain gene mutations (NF1, KEAP1/NRF2, or LKB1). The goal is to see if stopping the…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial tests a combination of three drugs—ZEN003694, nivolumab, and ipilimumab—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink or stabilize the canc…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for Hard-to-Treat cancers: targeted immunotherapy trial launches
Disease control OngoingThis study tests whether the immunotherapy drug nivolumab can help control cancer in people with metastatic or inoperable solid tumors that have a specific genetic change (ARID1A mutation) and a protein marker (CXCL13). Sixteen participants will receive nivolumab to boost their i…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests a combination of two drugs, veliparib and topotecan, in people with solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 88 adults are taking part in this early…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New combo targets Hard-to-Treat cancers with gene mutations
Disease control TerminatedThis study tests whether adding a targeted drug (ipatasertib) to standard chemotherapy (paclitaxel) can shrink or slow advanced solid tumors that have PTEN or AKT gene changes. About 33 adults whose cancer did not respond to taxane chemotherapy will receive the combination. The g…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of combining two drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find the highest dose that is safe and to see if the combination can…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs (copanlisib, olaparib, and durvalumab) in 39 adults with advanced solid tumors that have spread or cannot be removed. The goal is to find the safest dose and see how well the drugs work together. Participants must have spe…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Cancer drug trial pulled before it even started
Disease control TerminatedThis was a Phase I trial testing a drug called CB-5339 in people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the best dose and check for side effects. However, the study was withdrawn before enrolling any partic…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
New hope for rare cancers: immune-boosting drug shows promise
Disease control OngoingThis study tests a drug called pembrolizumab in 157 people with rare tumors that cannot be removed by surgery or have spread. The drug helps the immune system fight cancer by blocking a protein that slows it down. The main goal is to see if the drug can stop tumors from growing f…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Cement shield for fragile spines: can it stop fractures after cancer radiation?
Prevention OngoingThis study is testing whether injecting medical cement into the spine can prevent fractures in cancer patients receiving high-dose radiation to spinal tumors. Researchers are comparing patients who receive the cement procedure alongside radiation to those who receive radiation al…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Apr 23, 2026 12:43 UTC
-
Brain cancer patients may keep quality of life with early mental support
Symptom relief OngoingThis study tests whether early visits with a brain health specialist can help people with cancer that has spread to the brain maintain their quality of life after radiation therapy. About 110 adults with stage IV solid tumors and brain metastases will receive neuropsychological c…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
Honest placebo: a sugar pill that fights cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill that patients know contains no active drug—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply believing in treat…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 12, 2026 13:40 UTC
-
New combo targets cancer fatigue: exercise plus steroid shows promise
Symptom relief OngoingThis study tests whether adding a steroid drug called dexamethasone to a physical activity program can better reduce severe fatigue in people with advanced cancer. About 99 participants will be assigned to exercise alone or exercise plus the drug. The goal is to see if the combin…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 11, 2026 20:49 UTC
-
Money stress in cancer care: new study tests financial coaching
Symptom relief OngoingThis study tests whether a financial navigation program can reduce money-related stress for cancer patients and their caregivers. About 331 adults with advanced cancer or blood cancers will receive either financial coaching or usual care. The goal is to see if this help lowers fi…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated May 11, 2026 20:48 UTC
-
New combo aims to fight cancer fatigue
Symptom relief OngoingThis study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can lessen severe fatigue in people with advanced solid tumors that have spread or come back. About 129 participants will receive the drug and support for several weeks.…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 11, 2026 20:39 UTC
-
Cancer patients with COVID-19: new study tracks outcomes
Knowledge-focused OngoingThis study follows nearly 1,900 cancer patients who tested positive for COVID-19 to learn how the virus impacts their health and cancer treatment. Researchers collect blood samples, medical records, and images to identify factors linked to severe COVID-19 and changes in cancer th…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 04:27 UTC
-
Which method works best for delivering palliative care to cancer patients?
Knowledge-focused OngoingThis study looks at two different ways to provide palliative care—a type of care that helps with symptoms and stress—to people with advanced cancer and their caregivers. About 208 patients and their caregivers will take part. The goal is to see which method helps more patients co…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated May 17, 2026 04:25 UTC
-
Brain waves reveal if unresponsive patients hear loved ones in final days
Knowledge-focused TerminatedThis study uses a brain wave test (EEG) to check if cancer patients who appear unresponsive in their last days can still hear or feel. Researchers will measure brain activity before and after speaking to them. The goal is to help families and doctors understand what patients may …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Cancer weight loss study also targets caregiver stress
Knowledge-focused OngoingThis study measures how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and appetite loss) and examines the emotional toll on both patients and their primary caregivers. Researchers will track weight changes and use questionnaires …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Scientists peek inside tumors to see how new drug fights HER2 cancers
Knowledge-focused OngoingThis early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure chang…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
Expert tumor board aims to unlock genetic secrets for advanced cancer patients
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will take part, and their doctors will either use the t…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC
-
Short video boosts cancer Patients' understanding of genetic tests
Knowledge-focused OngoingThis study tests whether watching a short video helps people with metastatic cancer understand tumor genomic testing better. About 243 adults with cancer that has spread will watch the video and answer questions before and after. The goal is to see if the video improves knowledge…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 05, 2026 11:53 UTC